Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's Disease: A case study and review of the literature

Journal of Neuro-Oncology

Volumn 80, Issue 1, 2006, Pages 91-95

  Basu, Sandip ^a   Nair, Narendra ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

FDGPET; Neurofibromatosis 1; Neurofibrosarcoma; VonRecklinghausen's Disease

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMOROPOPLITEAL BYPASS; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; MALE; MALIGNANT TRANSFORMATION; NEUROFIBROMATOSIS; NEUROFIBROSARCOMA; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POPLITEAL ARTERY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RECURRENT DISEASE; WHOLE BODY SCINTISCANNING;

ADULT; CELL TRANSFORMATION, NEOPLASTIC; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; SARCOMA;

EID: 33749172423     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9161-x     Document Type: Article

References (17)

1. Barker D, Wright E, Nguyen K et al (1987) Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236(4805):1100-1102
2. DeClue JE, Cohen BD, Lowy DR (1991) Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci USA 88(22):9914-9918
3. Gutmann DH, Collins FS (1993) The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10(3):335-343
4. Wolkenstein P, Freche B, Zeller J, Revuz J (1996) Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dermatol 132:1333-1336
5. Friedman JM, Birch PH (1997) Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70:138-143
6. Cotran RS, Kumar V, Robbins SL (1994) Robbins pathologic basis of disease, 5th edn. W.B. Saunders, Philadelphia, pp 1353
7. National Institutes of Health (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45(5):575-578
8. DeBella K, Szudek J, Friedman JM (2000) Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105:608-614
9. Riccardi VM (1992) Neurofibromatosis. Phenotype, natural history and pathogenesis, 2nd edn. John Hopkins University Press, Baltimore
10. Seizinger BR (1993) NF 1: A prevalent cause of tumorigenesis in human cancers? Nature Genet 3:97-99
11. Riccardi VM (1992) Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr 22:66-107
12. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J (1992) Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356(6371):663-664
13. Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF et al (2000) Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatr 68(3):353-357
14. Chander S, Westphal SM, Zak IT, Bloom DA, Zingas AP, Joyrich RN et al (2004) Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med 29(7):415-418
15. Otsuka H, Graham MM, Kubo A, Nishitani H (2005) FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: A case report. Ann Nucl Med 19(1):55-58
16. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M et al (2006) Eur J Nucl Med Mol Imaging 11:1-5 [Epub ahead of print]
17. Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer section sign G et al (2003) Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29(6):536-541